Skip to main content
Clinical Trials/IRCT20110423006257N3
IRCT20110423006257N3
Recruiting
Phase 3

A clinical trial to evaluate the therapeutic effects of thalidomide in patients with COVID-19 infection

Arak University of Medical Sciences0 sites66 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Covid 19.
Sponsor
Arak University of Medical Sciences
Enrollment
66
Status
Recruiting
Last Updated
5 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
5 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Duration of the symptoms less than 10 days
  • Lymphocyte count less than 1000 per microliter
  • Quantitative CRP more than 1\.5 times normal
  • Positive pcr test of covid 19
  • O2 sat less than 93%
  • Respiratory rate less than 24
  • Chest CT scan findings compatible with COVID\-19 Pneumonia

Exclusion Criteria

  • History of chronic disease
  • Pregnant women, lactating women , sexually active premenopausal women
  • Loss of consciousness
  • Liver enzymes more than 5 times normal

Outcomes

Primary Outcomes

Not specified

Similar Trials